Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Miami Myeloma MRD 2023
06 April 2023 | Virtual Meeting
The Miami Myeloma MRD 2023 Meeting was hosted by the Sylvester Comprehensive Cancer Center’s Myeloma Research Institute, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma. View the presentations and discussions from the meeting below.
Current era of MRD testing
MAIA study: sustained MRD status in non-transplant eligible patients
Nizar Bahlis Arnie Charbonneau Cancer Institute, Calgary, Canada
DETERMINATION study: upfront vs delayed transplant, by MRD status?
Paul Richardson Dana-Farber Cancer Institute, Boston, MA, United States
CASTOR study: MRD status in relapsed/refractory myeloma
Katja Weisel University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Sustained MRD negativity on maintenance therapy
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Session 1 discussion
Live discussion: patient perspectives on MRD testing in myeloma
Patient perspectives on MRD testing in myeloma
Yelak Biru International Myeloma Foundation, Los Angeles, CA, United States
Current and emerging technologies for tracking MRD in myeloma
Mass-spec using MALDI-TOF, BindingSite Technology
Niels Weinhold Heidelberg University, Heidelberg, Germany
Whole genome sequencing of circulating tumor cells
Jean-Baptiste Alberge Dana-Farber Cancer Institute, Boston, MA, United States
Individualized serum peptides, Sebia Technology
Katie Thoren University of Miami, Miami, FL, United States
V(D)J tracking in bone marrow and peripheral blood, Adaptive Technology
Malin Hultcrantz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Session 2 discussion
Live discussion: perspectives on available and new MRD assays in myeloma
Perspectives on available and new MRD assays in myeloma
George Mulligan Multiple Myeloma Research Foundation, Boston, MA, United States
Fireside chat with the FDA: MRD in myeloma, today and tomorrow
Fireside chat with the FDA: MRD in myeloma, today and tomorrow
Nicole Gormley Food and Drug Administration (FDA), Bethesda, MD, United States
Treatment decisions based on MRD in myeloma
Update from the MASTER trial
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
University of Chicago treatment cessation study
Benjamin Derman University of Chicago Medical Center, Chicago, IL, United States
MSKCC treatment cessation study
Neha Korde Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Role of normalization of bone marrow microenvironment
David Coffey Sylvester Comprehensive Cancer Center, Miami, FL, United States
Session 3 discussion
Live discussion: using MRD testing in the real world
Using MRD testing in the real world
Jennifer Ahlstrom HealthTree Foundation for Multiple Myeloma, Salt Lake City, UT, United States
The Miami Myeloma MRD 2023 Meeting was supported by:
VJHemOnc was pleased to be media partner for the Miami Myeloma MRD 2023 Meeting
